Applied DNA Sciences (APDN) Regains Nasdaq Compliance

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that on April 7, 2025, it received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq"), informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement").

As previously reported, the Company was notified on November 12, 2024, that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Minimum Bid Price Requirement. To regain compliance with the Minimum Bid Price Requirement, the closing bid of the Company's common stock needed to be at least $1.00 for a minimum of 10 consecutive business days.

Nasdaq determined that for 16 consecutive business days, from March 14 through April 4, 2025, the closing bid price of the Company's common stock was $1.00 per share or greater. Accordingly, the Company has regained compliance with the Minimum Bid Price Requirement, and Nasdaq now considers this matter closed.

You May Also Be Interested In

• Nscale targets up to $3B in US IPO as soon as September - Bloomberg
• SEC accuses ex-BofA senior banker Satsky of insider trading - Bloomberg
• FTC files amicus brief challenging Amgen's Enbrel patent acquisition